Pharma BD Deal Intelligence

Gilead Sciences Inc. / Tubulis GmbH

2026 · Acquisition/Merger · $5.0B · Complete

Gilead acquired German ADC specialist Tubulis for $3.15B upfront (cash-free, debt-free) plus up to $1.85B in milestones (~$5B total). The acquisition closed on May 21, 2026. It brings lead asset TUB-040 (NaPi2b TOPO1i ADC in Phase 1b/2 for platinum-resistant ovarian cancer; FDA Fast Track), TUB-030 (5T4 ADC), and a next-gen ADC platform. The Tubulis team remains in Munich as The Tubulis ADC Innovation Center, a dedicated next-gen ADC hub within Gilead.

Key facts

• Announced Apr 07, 2026
• Closed May 21, 2026
• Deal value $5.0B
• Deal type Acquisition/Merger
• Therapeutic area Platinum-resistant ovarian cancer (TUB-040); multiple solid tumors (TUB-030)
• Indications Platinum-resistant ovarian cancer (TUB-040); multiple solid tumors (TUB-030)
• Key assets TUB-040 (NaPi2b-directed TOPO1i ADC) and TUB-030 (5T4-targeted ADC)
• Mechanism Next-generation antibody-drug conjugates using Tubulis proprietary P5 conjugation / Tubutecan linker-payload platform

← Browse all deals  ·  How we score deals